Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59,385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. Karoulia Z, et al. Among authors: wu y, wu x. Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. Cancer Cell. 2016. PMID: 27622340 Free article. No abstract available.
Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI. Adamopoulos C, et al. Among authors: wu x. Cancer Discov. 2021 Jul;11(7):1716-1735. doi: 10.1158/2159-8290.CD-20-1351. Epub 2021 Feb 10. Cancer Discov. 2021. PMID: 33568355 Free PMC article.
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed TA, Karoulia Z, Adamopoulos C, Wang H, Wang L, Xie L, Liu J, Ueberheide B, Aaronson SA, Chen X, Buchanan SG, Sellers WR, Jin J, Poulikakos PI. Wu X, et al. Nat Cancer. 2021 Apr;2(4):429-443. doi: 10.1038/s43018-021-00174-z. Epub 2021 Mar 1. Nat Cancer. 2021. PMID: 34568836 Free PMC article.
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.
Xu J, Yu X, Martin TC, Bansal A, Cheung K, Lubin A, Stratikopoulos E, Cahuzac KM, Wang L, Xie L, Zhou R, Shen Y, Wu X, Yao S, Qiao R, Poulikakos PI, Chen X, Liu J, Jin J, Parsons R. Xu J, et al. Among authors: wu x. Cancer Discov. 2021 Dec 1;11(12):3064-3089. doi: 10.1158/2159-8290.CD-20-0815. Cancer Discov. 2021. PMID: 34301793 Free PMC article.
Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
Santini CC, Longden J, Schoof EM, Simpson CD, Jeschke GR, Creixell P, Kim J, Wu X, Turk BE, Rosen N, Poulikakos PI, Linding R. Santini CC, et al. Among authors: wu x. Sci Rep. 2019 Jul 26;9(1):10865. doi: 10.1038/s41598-019-47245-x. Sci Rep. 2019. PMID: 31350469 Free PMC article.
Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents.
Stratikopoulos EE, Kiess N, Szabolcs M, Pegno S, Kakit C, Wu X, Poulikakos PI, Cheung P, Schmidt H, Parsons R. Stratikopoulos EE, et al. Among authors: wu x. Oncogene. 2019 Jan;38(1):47-59. doi: 10.1038/s41388-018-0436-4. Epub 2018 Aug 3. Oncogene. 2019. PMID: 30076411 Free PMC article.
59,385 results
You have reached the last available page of results. Please see the User Guide for more information.